New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
Artios, Synnovation and Novartis show mere glimmers of activity.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
